News & Events > Toxikon in the News

Toxikon in the News

Toxikon’s CEO Discusses Pharmacogenomics with Drug Discovery News

Dr. Laxman Desai, president and CEO of Toxikon Corp., discusses trends in cancer research in the September 2010 issue of Drug Discovery News.

In the Special Report, "Pharmacogenomics harnesses power of prediction, personalization," Dr. Desai says that while it is still in its infancy; knowledge of pharmacogenomics is increasing rapidly.

"Life science industries continue to delve into it and develop gene expression profiles for different classes of chemical carcinogens and possibly mutagens," Dr. Desai says. "Pharmacogenomics is impacting in a good way because, at some point, we will be able to develop and direct new drugs in a more efficient and more personalized fashion when it comes to treating diseases, like cancer."

To read the article, follow this link to Drug Discovery News.

WEBINAR: Toxikon's Validation/Quality Systems Engineer Discusses Software Validation Efficiencies

The latest Drug Safety Executive Council (DSEC) webinar, "Reducing the Time & Costs of GLP Software Validation," features Nick Vickers , Toxikon's Validation and Quality Systems Engineer, and a host of other IT experts. Click here to listen to a recording of the session. 


 

Want to learn more? Click here to contact us.

Call 800.458.4141
between 8:00 - 6:00 EST.
or email info@toxikon.com

Toxikon | Drug Research and Development | Preclinical Contract Research Organization (CRO)
Center For Drug Research And Development, Drug Development Research, Drug Research And Development, Preclinical Contract Research, Preclinical Contract Research Organization, CRO, Biomarker Drug Development, medical device, preclinical contract research, lab work, combination devices, animal models, cardiovascular, ocular, orthopedic and neurological devices, biocompatibility toxicity, sensitization, irritation, specialized imaging, measurement and monitoring equipment
Toxikon is a preclinical contract research organization (CRO) dedicated to collaborating with biotech, pharmaceutical and medical device researchers to deliver exceptional drug research and development services from concept to final product.